

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6055845

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
SEOUL NATIONAL UNIVERSITY R&BD FOUNDATION	02/06/2020
RECEIVING PARTY DATA	
Name:	THERASID BIOSCIENCE INC.
Street Address:	3F ANB TOWER
Internal Address:	331 PANGYO-RO, BUNDANG-GU
City:	SEONGNAM-SI, GYEONGGI-DO
State/Country:	KOREA, REPUBLIC OF
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	10407388
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	lmurphy@dsiplaw.com
Correspondent Name:	SERVILLA WHITNEY LLC
Address Line 1:	33 WOOD AVENUE SOUTH
Address Line 2:	SUITE 830
Address Line 4:	ISELIN, NEW JERSEY 08830
ATTORNEY DOCKET NUMBER:	CNP0024
NAME OF SUBMITTER:	RORY P. ALEGRIA
SIGNATURE:	/Rory P. Alegria, Reg. #66947/
DATE SIGNED:	04/10/2020
Total Attachments: 2	
source=00888005#page1.tif	
source=00888005#page2.tif	

SHORT-FORM PATENT LICENSE FOR RECORDAL

WHEREAS, SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, having an address at 1, Gwanak-Ro Gwanak-Gu Seoul 08826, Republic of Korea (hereinafter "SNU"), is the assignee of the entire right, title and interest in and to U.S. Patent No. 10,407,388 entitled NOVEL THIOUREA DERIVATIVES AS ACTIVATORS OF ROR α AND PHARMACEUTICAL COMPOSITION CONTAINING SAME;

AND WHEREAS, pursuant to a License Agreement effective February 6, 2020, Therasid Bioscience Inc., having an address at 3F ABN Tower, 331 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea (hereinafter "THERASID"), is the exclusive licensee to the aforementioned patent U.S. Patent No. 10,407,388;

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, SNU has licensed the aforementioned patent U.S. Patent No. 10,407,388 to THERASID as the exclusive licensee for the term beginning on February 6, 2020 and ending as of the expiration date of the aforementioned patent U.S. Patent No. 10,407,388.

SNU R&DB FOUNDATION (as licensor)

BY:

Kim Yang Geun

NAME:

Kim Yang Geun

TITLE:


Senior Director

Hwang Wook, Hwang Wook

Witness

Therasid Bioscience Inc. (as exclusive licensee)

BY:




NAME:

Heung-Jae, Kim

TITLE:

CEO

 Wonyoung Kwak

Witness